Page 2 - Access Pathway News Today

Data from novel proprietary neurotropic adeno-associated virus delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier penetration in non-human primates following intravenous...

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports...

- Eisai Co., Ltd. announced today that the Scientific Advisory Group will convene to discuss the marketing authorization application of lecanemab , which is currently under review by the European...

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditionsLONDON, Dec. 19, 2023 -- Compass Pathways plc , a biotechnology company...

ABK Biomedical successfully secured Breakthrough Device Designation from the FDA on December 5, 2023, for its Eye90 microspheres device, which is indicated for the treatment of...

TOKYO and CAMBRIDGE, Mass., December 12, 2023 - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI®...

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depressionLONDON, Dec. 06, 2023 -- Compass Pathways plc , a biotechnology company dedicated to accelerating patient...

Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) has been recommended by the National Institute for Health and Care Excellence (NICE) for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1Durvalumab is AstraZeneca UK&rsq...

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Nov 16, 2023--